Last reviewed · How we verify
COVID-19 vaccines
COVID-19 vaccines developed by the University of British Columbia stimulate the immune system to recognize and neutralize the SARS-CoV-2 virus.
COVID-19 vaccines developed by the University of British Columbia stimulate the immune system to recognize and neutralize the SARS-CoV-2 virus. Used for Prevention of COVID-19 infection and disease.
At a glance
| Generic name | COVID-19 vaccines |
|---|---|
| Also known as | Janssen COVID19 vaccine, Astra Zeneca COVID19 vaccine, Comirnaty Pfizer COVID19 vaccine, Moderna COVID19 vaccine, BNT162b2 |
| Sponsor | University of British Columbia |
| Drug class | vaccine |
| Target | SARS-CoV-2 spike protein and/or nucleocapsid protein |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
These vaccines work by presenting viral antigens (typically spike protein or nucleocapsid protein components) to the immune system, triggering both antibody and T-cell mediated immune responses. This prepares the body to rapidly recognize and eliminate SARS-CoV-2 if exposed, reducing infection risk and severity of disease.
Approved indications
- Prevention of COVID-19 infection and disease
Common side effects
- Injection site pain or swelling
- Fatigue
- Headache
- Myalgia
- Fever
- Chills
Key clinical trials
- A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations (PHASE4)
- Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults (PHASE1)
- Assessing Safety of Coronavirus Infection (COVID-19) Messenger RNA (mRNA) Vaccine Administration in the Setting of a Previous Adverse Reaction (PHASE4)
- A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults (PHASE1)
- Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals (PHASE2, PHASE3)
- Influenza Vaccination, ACEI and ARB in the Evolution of SARS-CoV2 Infection
- Evaluation of Full Versus Fractional Dose of COVID-19 Vaccine Given as a Booster for the Prevention of COVID-19 in Adults in Mongolia. (PHASE3)
- COVID-19 Breakthrough Infection in Fully Vaccinated People and in People Who Received a Booster Dose
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |